Allergy and immunology


Basic research

Cardiovascular medicine

Complementary medicine and alternative therapies

Critical care / intensive care

Dentistry / oral medicine


Emergency medicine




Evidence-based medicine



Geriatric medicine / aging

Haematology / blood transfusion

Health economics

Health policy

History of medicine

Infectious diseases

Internal medicine

Laboratory medicine

Medical education

Medical informatics



Nutrition and metabolism

Obstetrics and gynaecology

Occupational and environmental medicine



Organisation of health care

Otolaryngology / head and neck surgery


Palliative care


Patient-physician relationship

Pharmacology and therapeutics

Primary care, family medicine

Psychiatry and psychotherapy


Public health

Quality of care


Rehabilitation medicine

Renal medicine

Respiratory medicine


Sexual medicine

Sports medicine

Statistics and research methods



Travel medicine


Ops! No article found. Reset filter

Towards novel reimbursement models for expensive advanced therapy medicinal products (ATMPs)

Original article
Picecchi D, Bertram K, Brücher D, Bauer M
Swiss Med Wkly. 2020;150:w20355

This article analyses the current legal framework in Switzerland and critically evaluates existing reimbursement models, particularly with respect to their adaptation for advanced therapy medicinal products. As a promising reimbursement arrangement, this paper proposes a model combining outcome-based instalment payments with aspects of the pay for performance and the annuity payment model. 

The economic and public health impact of influenza vaccinations: contributions of Swiss pharmacies in the 2016/17 and 2017/18 influenza seasons and implications for vaccination policy

Original article
Brunner I, Schmedders K, Wolfensberger A, Schreiber PW, Kuster SP
Swiss Med Wkly. 2019;149:w20161

The economic and public health impact of prescriptionless vaccination against influenza in healthy adults in Switzerland has not been studied yet.

Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland

Original article
Blach S, Schaetti C, Bruggmann P, Negro F, Razavi H
Swiss Med Wkly. 2019;149:w20026

Increasing the number of patients treated and treating all fibrosis stages is cost-effective compared against the historical base case and could achieve a break-even by 2031 at a price of 27,900 CHF.

Quality and cost considerations in hyponatraemic patients needing hospitalisation

Original article
Althaus AE, Krapf R
Swiss Med Wkly. 2018;148:w14662

Hyponatraemia is the most common electrolyte disorder encountered in hospitalised patients and has an impact on outcome and survival. However, the risk factors are not yet sufficiently known.

A buyers’ club to improve access to hepatitis C treatment for vulnerable populations

Review article: Biomedical intelligence
Vernaz N, Calmy A, Hurst S, Jackson Y, Negro F, Perrier A, Wolff H
Swiss Med Wkly. 2018;148:w14649

High costs are an important barrier to treatment access for vulnerable and often uninsured patients with hepatitis C.

Predictors for shorter and longer length of hospital stay outliers: a retrospective case-control study of 8247 patients at a university hospital trauma department

Original article
Jentzsch T, Seifert B, Neuhaus V, Moos RM
Swiss Med Wkly. 2018;148:w14650

Providing efficient healthcare is important for hospitals. Shorter and longer length of hospital stay (LOS) outliers influence financial results and reimbursement.

Ovarian cancer in Switzerland: incidence and treatment according to hospital registry data

Original article
Wieser S, Schmidt M, Kind AB, Heinzelmann-Schwarz VA
Swiss Med Wkly. 2018;148:w14647

For the first time in Switzerland, the Swiss hospital registry was used to examine the incidence of ovarian cancer as well as its treatment episodes and costs.

Adaptation of cost-effectiveness analyses to a single country: the case of bariatric surgery for obesity and overweight

Systematic review
Ademi Z, Tomonaga Y, van Stiphout J, Glinz D, Gloy V, Raatz H, Bucher HC, Schwenkglenks M
Swiss Med Wkly. 2018;148:w14626

There is a relatively broad international literature on the cost effectiveness of bariatric surgery, but no systematic reviews that examine the transferability of international cost-effectiveness results for Switzerland or another single country.

Directing citizens to create advance directives

Review article: Biomedical intelligence
Haesen S, Shaw D
Swiss Med Wkly. 2018;148:w14628

In Switzerland, it is now mandatory for medical staff to act according to patients’ advance directives. Unfortunately, even though many people know about their ­existence, only a small minority actually draft them.

Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction

Original article
Ademi Z, Pfeil AM, Hancock E, Trueman D, Haroun RH, Deschaseaux C, Schwenkglenks M
Swiss Med Wkly. 2017;147:w14533

Sacubitril/valsartan, an angiotensin-receptor-neprilysin-inhibitor, is a novel oral therapy proposed in the current guidelines for the treatment of heart failure in patients with reduced left ventricular ejection fraction.

Verpassen Sie keinen Artikel!